Open AccessMRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment
Author(s) -
Juliette Eroukhmanoff,
Isabelle Téjédor,
Iulia Potorac,
Thomas Cuny,
JeanFrançois Bonneville,
Henry Dufour,
G. Weryha,
Albert Beckers,
Philippe Touraine,
Thierry Brue,
Frédéric Castinetti
Publication year - 2017
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-16-0897
Subject(s) - cabergoline , prolactin , medicine , prolactinoma , asymptomatic , endocrinology , dopamine agonist , dopamine , magnetic resonance imaging , agonist , urology , hormone , receptor , radiology
Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom